Cost-effectiveness of NALIRIFOX versus Nab-paclitaxel and gemcitabine in previously untreated metastatic pancreatic ductal adenocarcinoma

被引：0
|
作者：
Wenjie Liu [1 ]
Yuting Fang [1 ]
Chao Zhang [2 ]
Midan Xiang [1 ]
Lijuan Qi [3 ]
Aijiang Su [2 ]
Yongkun Sun [1 ]
机构：
[1] Chinese Academy of Medical Sciences and Peking Union Medical College,National Clinical Research Center for Cancer/Cancer Hospital, National Cancer Center
[2] Beijing Chaoyang District Sanhuan Cancer Hospital,Department of Medical Oncology
[3] Chinese Academy of Medical Sciences,National Cancer Center, National Clinical Research Center for Cancer/Hebei Cancer Hospital
来源：
BMC Gastroenterology | / 25卷 / 1期
关键词：
Metastatic pancreatic ductal adenocarcinoma; NALIRIFOX; Nab-paclitaxel and gemcitabine; Cost-effectiveness;
D O I：
10.1186/s12876-025-03867-2
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [21] First line gemcitabine and nab-paclitaxel chemotherapy for localized pancreatic ductal adenocarcinoma.
    Gulhati, Pat
    Prakash, Laura
    Katz, Matthew H. G.
    Wang, Xuemei
    Javle, Milind M.
    Shroff, Rachna T.
    Fogelman, David R.
    Lee, Jeffrey Edwin
    Tzeng, Ching-Wei David
    Lee, Jeffrey H.
    Weston, Brian
    Tamm, Eric P.
    Bhosale, Priya
    Koay, Eugene Jon
    Maitra, Anirban
    Wang, Huamin
    Wolff, Robert A.
    Varadhachary, Gauri R.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
  • [22] Efficacy and tolerance of gemcitabine and nab-paclitaxel in elderly patients with advanced pancreatic ductal adenocarcinoma
    Pignon, Flore
    Turpin, Anthony
    Hentic, Olivia
    Coriat, Romain
    Salmon, Emma
    Baumgaertner, Isabelle
    Bertrand, Nicolas
    Levy, Philippe
    Rebours, Vinciane
    Hammel, Pascal
    de Mestier, Louis
    PANCREATOLOGY, 2021, 21 (06) : 1064 - 1070
  • [23] First-Line Gemcitabine and Nab-Paclitaxel Chemotherapy for Localized Pancreatic Ductal Adenocarcinoma
    Gulhati, Pat
    Prakash, Laura
    Katz, Matthew H. G.
    Wang, Xuemei
    Javle, Milind
    Shroff, Rachna
    Fogelman, David
    Lee, Jeffrey E.
    Tzeng, Ching-Wei D.
    Lee, Jeffrey H.
    Weston, Brian
    Tamm, Eric
    Bhosale, Priya
    Koay, Eugene J.
    Maitra, Anirban
    Wang, Huamin
    Wolff, Robert A.
    Varadhachary, Gauri R.
    ANNALS OF SURGICAL ONCOLOGY, 2019, 26 (02) : 619 - 627
  • [24] First-Line Gemcitabine and Nab-Paclitaxel Chemotherapy for Localized Pancreatic Ductal Adenocarcinoma
    Pat Gulhati
    Laura Prakash
    Matthew H. G. Katz
    Xuemei Wang
    Milind Javle
    Rachna Shroff
    David Fogelman
    Jeffrey E. Lee
    Ching-Wei D. Tzeng
    Jeffrey H. Lee
    Brian Weston
    Eric Tamm
    Priya Bhosale
    Eugene J. Koay
    Anirban Maitra
    Huamin Wang
    Robert A. Wolff
    Gauri R. Varadhachary
    Annals of Surgical Oncology, 2019, 26 : 619 - 627
  • [25] Safety and clinical efficacy of IOA-289, a novel autotaxin inhibitor, plus gemcitabine and nab-paclitaxel (GnP) in patients with previously untreated metastatic pancreatic ductal adenocarcinoma (mPDAC)
    Melisi, Davide
    Quinzii, Alberto
    Valente, Monica
    Di Giacomo, Anna Maria
    Amato, Giovanni
    Simonetti, Elena
    Zecchetto, Camilla
    Casallino, Simona
    Leta, Luigi
    Messineo, Luisa
    Mendo, Lucia
    Hammett, Tracey
    Deken, Marcel
    Di Conza, Giusy
    Kaur, Paramjit
    Lahn, Michael M. F.
    Maio, Michele
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [26] Nab-paclitaxel and gemcitabine plus camrelizumab and radiotherapy versus nab-paclitaxel and gemcitabine alone for locally advanced pancreatic adenocarcinoma: a prospective cohort study
    Shuling Chen
    Jiaxin Li
    Aoran Dong
    Zelong Liu
    Meiyan Zhu
    Meng Jin
    Guangyan Wei
    Shuang Wu
    Yan Wang
    Yong Chen
    Zhenwei Peng
    Journal of Hematology & Oncology, 16
  • [27] Nab-paclitaxel and gemcitabine plus camrelizumab and radiotherapy versus nab-paclitaxel and gemcitabine alone for locally advanced pancreatic adenocarcinoma: a prospective cohort study
    Chen, Shuling
    Li, Jiaxin
    Dong, Aoran
    Liu, Zelong
    Zhu, Meiyan
    Jin, Meng
    Wei, Guangyan
    Wu, Shuang
    Wang, Yan
    Chen, Yong
    Peng, Zhenwei
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2023, 16 (01)
  • [28] Matters arising: On the cost-effectiveness for the Italian National Health Service of nab-paclitaxel plus gemcitabine vs gemcitabine alone in metastatic pancreatic cancer
    Lazzaro, Carlo
    JOURNAL OF THE EGYPTIAN PUBLIC HEALTH ASSOCIATION, 2024, 99 (01):
  • [29] Phase 1 dose-escalation study of momelotinib, a Janus kinase 1/2 inhibitor, combined with gemcitabine and nab-paclitaxel in patients with previously untreated metastatic pancreatic ductal adenocarcinoma
    Ng, Kimmie
    Hendifar, Andrew
    Starodub, Alexander
    Chaves, Jorge
    Yang, Yingsi
    Koh, Brian
    Barbie, David
    Hahn, William C.
    Fuchs, Charles S.
    INVESTIGATIONAL NEW DRUGS, 2019, 37 (01) : 159 - 165
  • [30] QALY WEIGHTINGS BASED ON THE BURDEN OF ILLNESS APPLIED TO A UK COST-EFFECTIVENESS ANALYSIS OF NAB-PACLITAXEL plus GEMCITABINE VERSUS GEMCITABINE ALONE FOR THE TREATMENT OF METASTATIC PANCREATIC CANCER
    Cowell, W.
    Gladwell, D.
    Parnaby, A.
    VALUE IN HEALTH, 2014, 17 (07) : A642 - A642
12345